$XENE
Xenon Pharmaceuticals Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024057139 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $49.70M $44.25M
YoY Change 12.86% 11.98%
% of Gross Profit
Depreciation & Amortization $659.0K $599.0K
YoY Change 9.47% 69.21%
% of Gross Profit
Operating Expenses $69.10M $59.04M
YoY Change 24.23% 20.37%
Operating Profit -$69.10M -$59.04M
YoY Change 24.23% 20.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.85M $11.52M
YoY Change 36.56% 51.33%
Pretax Income -$58.26M -$47.52M
YoY Change 22.18% 14.68%
Income Tax -$333.0K $412.0K
% Of Pretax Income
Net Earnings -$57.92M -$47.93M
YoY Change 22.05% 14.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.62
Diluted Earnings Per Share -$0.75 -$0.62
COMMON SHARES
Basic Shares Outstanding 75.47M 75.43M
Diluted Shares Outstanding 77.67M 77.59M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $721.5M $699.6M
YoY Change 33.72% 32.74%
Cash & Equivalents $136.7M $58.90M
Short-Term Investments $584.8M $640.7M
Other Short-Term Assets $5.701M $6.769M
YoY Change 97.06% 65.66%
Inventory
Prepaid Expenses
Receivables $853.0K $833.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $728.1M $707.2M
YoY Change 33.69% 32.6%
LONG-TERM ASSETS
Property, Plant & Equipment $10.14M $9.393M
YoY Change 6.01% 17.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $129.1M $185.8M
YoY Change 14.63% 15.96%
Other Assets $8.149M $7.706M
YoY Change -2.16% -5.79%
Total Long-Term Assets $155.9M $211.8M
YoY Change 11.15% 13.57%
TOTAL ASSETS
Total Short-Term Assets $728.1M $707.2M
Total Long-Term Assets $155.9M $211.8M
Total Assets $884.0M $919.0M
YoY Change 29.07% 27.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.60M $6.536M
YoY Change -12.55% -46.32%
Accrued Expenses $20.69M $15.69M
YoY Change 28.97% 52.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.29M $22.22M
YoY Change 11.1% -1.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.679M $9.102M
YoY Change -15.6% -12.76%
Total Long-Term Liabilities $8.679M $9.102M
YoY Change -15.6% -12.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.29M $22.22M
Total Long-Term Liabilities $8.679M $9.102M
Total Liabilities $39.96M $31.33M
YoY Change 3.96% -4.86%
SHAREHOLDERS EQUITY
Retained Earnings -$771.0M -$713.1M
YoY Change 34.8% 35.96%
Common Stock $1.617B $1.603B
YoY Change 32.38% 32.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $844.0M $887.7M
YoY Change
Total Liabilities & Shareholders Equity $884.0M $919.0M
YoY Change 29.07% 27.67%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$57.92M -$47.93M
YoY Change 22.05% 14.87%
Depreciation, Depletion And Amortization $659.0K $599.0K
YoY Change 9.47% 69.21%
Cash From Operating Activities -$32.68M -$43.18M
YoY Change -1.63% 25.48%
INVESTING ACTIVITIES
Capital Expenditures $1.514M $188.0K
YoY Change -29.02% -91.48%
Acquisitions
YoY Change
Other Investing Activities $112.2M -$46.01M
YoY Change 273.67% -194.24%
Cash From Investing Activities $110.7M -$46.20M
YoY Change 296.81% -199.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -32.68M -43.18M
Cash From Investing Activities 110.7M -46.20M
Cash From Financing Activities
Net Change In Cash 78.04M -89.75M
YoY Change -1567.19% -831.43%
FREE CASH FLOW
Cash From Operating Activities -$32.68M -$43.18M
Capital Expenditures $1.514M $188.0K
Free Cash Flow -$34.19M -$43.37M
YoY Change -3.28% 18.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001582313
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2024Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36687
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
XENON PHARMACEUTICALS INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0661854
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200-3650 Gilmore Way
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Burnaby
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2024Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5G 4W8
CY2024Q1 dei City Area Code
CityAreaCode
604
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
484-3300
CY2024Q1 dei Security12b Title
Security12bTitle
Common Shares, without par value
CY2024Q1 dei Trading Symbol
TradingSymbol
XENE
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75468883
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58896000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148643000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
640706000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
489439000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
833000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
874000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6769000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6006000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
707204000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
644962000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
185836000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
292792000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8884000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9193000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9393000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9653000
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
400000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
802000
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
7306000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
7396000
CY2024Q1 us-gaap Assets
Assets
919023000
CY2023Q4 us-gaap Assets
Assets
964798000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20900000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25974000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1323000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1299000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22223000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27273000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9102000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9604000
CY2024Q1 us-gaap Liabilities
Liabilities
31325000
CY2023Q4 us-gaap Liabilities
Liabilities
36877000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75459681
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75459681
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75370977
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75370977
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1438961000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1436374000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163577000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
156764000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-713071000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-665140000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1769000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-77000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
887698000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
927921000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
919023000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
964798000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44250000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39516000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14791000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9535000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
59041000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
49051000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-59041000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49051000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11355000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5423000
CY2023Q1 us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
1878000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
167000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
313000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11522000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7614000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47519000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41437000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
412000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
290000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-47931000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41727000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1692000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1180000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49623000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40547000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77594599
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77594599
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65724681
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65724681
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
721497000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41727000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5994000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1180000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
686944000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
927921000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-47931000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9400000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1692000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
887698000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-47931000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-41727000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
599000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
354000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
403000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
288000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9400000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5994000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-4000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
5000
CY2023Q1 us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
1878000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-38000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-226000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
673000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2931000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5018000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-594000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43178000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34411000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
188000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2206000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
176848000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
108282000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
130834000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
157110000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46202000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46622000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-367000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-89747000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12270000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148643000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57242000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58896000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69512000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
411000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
406000
CY2024Q1 xene Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
2587000
CY2023Q1 xene Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
635000
CY2023Q1 xene Fair Value Of Pre Funded Warrants Exercised
FairValueOfPreFundedWarrantsExercised
7379000
CY2023Q1 xene Increase In Operating Lease Liability And Accounts Receivable Related To Lease Incentives Claimed In The Period
IncreaseInOperatingLeaseLiabilityAndAccountsReceivableRelatedToLeaseIncentivesClaimedInThePeriod
1482000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-713071000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-47931000
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation:</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These unaudited interim consolidated financial statements are presented in U.S. dollars and include the accounts of the Company and its wholly-owned subsidiary, Xenon Pharmaceuticals USA Inc., a Delaware corporation. All intercompany transactions and balances have been eliminated on consolidation.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2023 included in the Company’s 2023 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on February 29, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2024 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company’s 2023 Annual Report on Form 10-K for the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with the exception of the policy described in note 3 below.</span></p>
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
826542000
CY2023Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
13867000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
768364000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
827321000
CY2024Q1 xene Available For Sale Debt Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
-779000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
826542000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
767451000
CY2023Q4 xene Available For Sale Debt Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
913000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
768364000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
412000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
412000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
208000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
197000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M2D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y11M23D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0387
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0392
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1269000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1747000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1815000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1802000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1102000
CY2024Q1 xene Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4193000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11928000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1503000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10425000
CY2024Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6430000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
8598000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3819000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7425000
CY2024Q1 xene Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
8942000
CY2023Q4 xene Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
8824000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1603000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
780000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
347000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20900000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25974000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2173081
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3103864
CY2024Q1 xene Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2023Q1 xene Number Of Warrants Exercised
NumberOfWarrantsExercised
-425003
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2173081
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2678861
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
2173081
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
2678861
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8894502
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.56
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7117782
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.75
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1983525
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.53
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1866548
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.29
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
180424
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
23.42
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
113677
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.49
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
18911
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
30.87
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
73400
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.49
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10678692
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.45
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8797253
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.12
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5419295
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.27
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4104317
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.04
CY2024Q1 xene Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
88704
CY2023Q1 xene Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
94319
CY2024Q1 xene Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
180424
CY2023Q1 xene Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
113677
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.69
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M17D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.89
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.19
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-057139-index-headers.html Edgar Link pending
0000950170-24-057139-index.html Edgar Link pending
0000950170-24-057139.txt Edgar Link pending
0000950170-24-057139-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xene-20240331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
xene-20240331.xsd Edgar Link pending
xene-ex10_1.htm Edgar Link pending
xene-ex31_1.htm Edgar Link pending
xene-ex31_2.htm Edgar Link pending
xene-ex32_1.htm Edgar Link pending
xene-ex32_2.htm Edgar Link pending
xene-20240331_htm.xml Edgar Link completed